Ryan Paul will present a practical guide around experiences with dulaglutide, the newly funded subcutaneous once weekly GLP1 receptor agonist for type 2 diabetes.
Key topics include:
-Identifying which of your patients will benefit from dulaglutide.
-Which patients meet the special authority criteria for dulaglutide and who should consider self-funding.
-When to choose dulaglutide or empagliflozin or both.
-How to discuss starting dulaglutide with patients and how to manage any adverse effects.
-Recommended follow up for patients on dulaglutide.
CHAPTERS:
00:00 intro
00:43 Ryan Paul Presentation
57:53 Audience Q&A
01:24:15 Close
